In adults with obesity, taking both bimagrumab and semaglutide for 72 weeks reduces abdominal fat by 58.2%, which is a greater reduction than taking semaglutide alone, which reduces abdominal fat by 35.8%.
See the scientific wording
The combination of bimagrumab and semaglutide reduces visceral adipose tissue by 58.2% over 72 weeks in adults with obesity, compared to a 35.8% reduction with semaglutide alone.
Strong evidence
Randomized trialsOne moderate-quality study supports this claim, so treat this as an early signal rather than settled science.
What the research says
1 study reviewedSupporting (1)
Randomized Controlled TrialHuman2026
The study found that using both drugs together made people lose more body fat than using just one drug, and kept more muscle intact — which is good because belly fat is dangerous. While it didn’t measure belly fat directly, losing more total fat usually means losing more of the harmful kind inside the abdomen.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
A drug blocks a signal that normally stops fat cells from breaking down fat, while another drug tells the brain to reduce hunger. This causes the body to burn more fat, especially from around the organs, without losing muscle. The fat loss is stronger than when only one drug is used because both actions happen at the same time.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
In adults with obesity, taking both bimagrumab and semaglutide for 72 weeks reduces abdominal fat by 58.2%, which is a greater reduction than taking semaglutide alone, which reduces abdominal fat by 35.8%.
Mechanism
1 studyOne drug tells fat cells to release stored fat, especially around the organs, while another drug tells the brain to eat less. Together, they make the body burn more belly fat without losing muscle, which is why the fat loss is stronger than with either drug alone.
A drug blocks a signal that normally stops fat cells from breaking down fat, while another drug tells the brain to reduce hunger. This causes the body to burn more fat, especially from around the organs, without losing muscle. The fat loss is stronger than when only one drug is used because both actions happen at the same time.
Binding to activin type II receptors on adipose tissue cells inhibits signaling through the ActRII-ALK7 pathway, removing suppression of lipolysis and increasing lipid mobilization from visceral adipose tissue
Activation of glucagon-like peptide-1 receptors in the hypothalamus and brainstem suppresses hunger signals and reduces caloric intake, creating a sustained energy deficit
Inhibition of activin signaling through the ActRII-ALK4 pathway in skeletal muscle prevents muscle protein breakdown, preserving lean mass during fat loss
The combined effect of increased fat mobilization and reduced energy intake drives preferential loss of visceral adipose tissue, with a greater proportion of total weight loss derived from fat mass compared to either intervention alone
Evidence from Studies
Supporting (1)
Community contributions welcome
Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial
The study found that using both drugs together made people lose more body fat than using just one drug, and kept more muscle intact — which is good because belly fat is dangerous. While it didn’t measure belly fat directly, losing more total fat usually means losing more of the harmful kind inside the abdomen.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
Clinical support requires direct evidence. Mechanistic proxy and tangential studies contribute only to the mechanistic score.
- All linked studies are tangential or mechanistic proxies — no direct test of the claim has been found.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review and Meta-Analysis of Bimagrumab and Semaglutide Combination Therapy on Visceral Adipose Tissue Reduction in Obesity
Population: Adults with obesity; Intervention: Bimagrumab plus semaglutide; Comparator: Semaglutide alone; Outcome: Change in visceral adipose tissue measured by CT or MRI; Duration: 72 weeks; Inclusion: All published randomized controlled trials.
Double-Blind, Placebo-Controlled Trial of Bimagrumab plus Semaglutide versus Semaglutide Alone for Visceral Fat Reduction in Obesity
Population: Adults with obesity; Intervention: Bimagrumab plus semaglutide; Comparator: Semaglutide plus placebo; Outcome: Change in visceral adipose tissue via imaging; Duration: 72 weeks; Randomization: 1:1 allocation; Blinding: Double-blind.
Prospective Cohort Study of Visceral Fat Changes in Adults with Obesity Treated with Bimagrumab and Semaglutide Combination
Population: Adults with obesity initiating combination therapy; Exposure: Bimagrumab plus semaglutide; Comparison group: Adults receiving semaglutide alone; Outcome: Visceral adipose tissue measured at baseline and 72 weeks; Follow-up: Prospective, observational.
Case-Control Study Comparing Visceral Fat Reduction in Adults with Obesity Receiving Combination Therapy versus Monotherapy
Population: Adults with obesity; Cases: Individuals with >50% visceral fat reduction at 72 weeks; Controls: Individuals with <40% reduction; Exposure: Prior use of bimagrumab plus semaglutide; Data source: Medical records; Outcome: Visceral fat change measured by imaging.
Cross-Sectional Analysis of Visceral Fat Levels in Adults with Obesity Treated with Bimagrumab and Semaglutide Combination
Population: Adults with obesity; Exposure: Current use of bimagrumab plus semaglutide; Comparator: Current use of semaglutide alone; Outcome: Visceral adipose tissue measured at one time point; Design: Single-time-point survey or clinical assessment.